HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.42
-0.19 (-1.22%)
At close: 4:00PM EDT

15.42 0.00 (0.00%)
After hours: 4:51PM EDT

Stock chart is not supported by your current browser
Previous Close15.61
Open15.51
Bid15.43 x 1300
Ask15.44 x 4000
Day's Range15.24 - 15.69
52 Week Range13.24 - 19.56
Volume769,578
Avg. Volume823,167
Market Cap2.238B
Beta (3Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-0.36
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.22
Trade prices are not sourced from all markets
  • Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
    PR Newswire23 hours ago

    Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

    SAN DIEGO, May 22, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019. The second target selected for development by argenx is human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases. Halozyme will receive a $10 million milestone payment during the current quarter from argenx for this target nomination and potential future payments of up to $160 million subject to achievement of specified development, regulatory and sales-based milestones.

  • Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
    Zacks2 days ago

    Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?

    Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.

  • Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019
    PR Newswire10 days ago

    Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019

    SAN DIEGO , May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America ...

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of HALO earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Halozyme Therapeutics Inc Earnings Call

  • Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript
    Motley Fool15 days ago

    Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript

    HALO earnings call for the period ending March 31, 2019.

  • Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates
    Zacks15 days ago

    Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates

    Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press15 days ago

    Halozyme Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had profit of 1 cent. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Halozyme Reports First Quarter 2019 Results
    PR Newswire15 days ago

    Halozyme Reports First Quarter 2019 Results

    - Revenue of $56.9 Million Compared to $30.9 Million in Prior-year Period - - ENHANZE® Partner Receives FDA Approval for Subcutaneous Formulation of Herceptin® - - Positive Phase 3 Trial Results Announced ...

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.

    Halozyme Therapeutics Inc NASDAQ/NGS:HALOView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for HALO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.05 billion over the last one-month into ETFs that hold HALO are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ACCESSWIRE16 days ago

    Halozyme Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 4:30 PM ...

  • Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development
    PR Newswire17 days ago

    Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development

    SAN DIEGO, May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A. Armour, M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP, as senior vice president, research and development, effective immediately. In this role, she will report to Dr. Helen Torley, president and chief executive officer. Dr. Armour will lead Halozyme's research, clinical development, regulatory, safety and pharmacovigilance efforts.

  • How Halozyme Therapeutics, Inc. (NASDAQ:HALO) Can Impact Your Portfolio Volatility
    Simply Wall St.22 days ago

    How Halozyme Therapeutics, Inc. (NASDAQ:HALO) Can Impact Your Portfolio Volatility

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) then it's worth thinking about how it...

  • Here’s What Hedge Funds Think About Halozyme Therapeutics, Inc. (HALO) Anymore
    Insider Monkey22 days ago

    Here’s What Hedge Funds Think About Halozyme Therapeutics, Inc. (HALO) Anymore

    Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]

  • Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
    Zacks23 days ago

    Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

    Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call
    PR Newswire29 days ago

    Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call

    SAN DIEGO , April 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...

  • Need To Know: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Insiders Have Been Selling Shares
    Simply Wall St.2 months ago

    Need To Know: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Insiders Have Been Selling Shares

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not...

  • 3 Cancer Treatment Stocks to Buy in March
    Motley Fool2 months ago

    3 Cancer Treatment Stocks to Buy in March

    Find out why these oncology-focused companies stand out as great opportunities right now.

  • TheStreet.com2 months ago

    2 Stocks You Definitely Should Consider Shorting This Week

    Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.

  • Top Ranked Momentum Stocks to Buy for March 4th
    Zacks3 months ago

    Top Ranked Momentum Stocks to Buy for March 4th

    Top Ranked Momentum Stocks to Buy for March 4th

  • Halozyme To Participate In Upcoming Investor Conferences
    PR Newswire3 months ago

    Halozyme To Participate In Upcoming Investor Conferences

    SAN DIEGO , March 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor ...

  • Halozyme Announces FDA Approval Of Herceptin Hylecta™
    PR Newswire3 months ago

    Halozyme Announces FDA Approval Of Herceptin Hylecta™

    SAN DIEGO, Feb. 28, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for Herceptin Hylecta™, a subcutaneous fixed-dose combination of trastuzumab and hyaluronidase-oysk. Herceptin Hylecta™ is approved for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.

  • Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript

    HALO earnings call for the period ending December 31, 2018.

  • Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

    Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 50.00% and 1.65%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Halozyme Therapeutics: 4Q Earnings Snapshot

    SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Thursday reported a fourth-quarter loss of $2.1 million, after reporting a profit in the same period a year earlier. The results topped Wall Street expectations. The biopharmaceutical company posted revenue of $60.2 million in the period, also beating Street forecasts.

  • Halozyme Reports Fourth Quarter And Full-Year 2018 Results
    PR Newswire3 months ago

    Halozyme Reports Fourth Quarter And Full-Year 2018 Results

    - ENHANZE® Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million - - 2019 Guidance Raised for Net Revenue and Year End Cash Balance ...